COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01161355
Recruitment Status : Completed
First Posted : July 13, 2010
Last Update Posted : February 9, 2011
Information provided by:

Brief Summary:
The primary objective of this study is to assess the absolute bioavailability and to evaluate pharmacokinetic parameters of a single oral dose and a radiolabelled intravenous microdose of [14C]AZD9668 in healthy male subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: AZD9668 Phase 1

Detailed Description:
This is an exploratory study to assess the absolute bioavailability of a single oral dose of AZD9668 with respect to an intra-venous microdose of [14C]AZD9668 in healthy male subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Exploratory Study to Assess the Absolute Bioavailability of a Single Oral Dose of AZD9668 With Respect to an Intra-venous Microdose of [14C]AZD9668 in Healthy Male Subjects
Study Start Date : June 2010
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Arm Intervention/treatment
Experimental: AZD9668
Tablets and intravenous (IV) dose
Drug: AZD9668
Tablets of AZD9668 and IV dose of [C14]AZD9668

Primary Outcome Measures :
  1. The absolute bioavailability and evaluation of pharmacokinetic parameters (AUC, AUC (0-t), Cmax, t½, tmax, and MRT of of a single oral dose and a radiolabelled intravenous microdose of [14C]AZD9668 [ Time Frame: Multiple Pharmacokinetic blood samples for up to 96 hours following drug administration ]

Secondary Outcome Measures :
  1. Safety and tolerability of AZD9668: Adverse events, clinical chemistry, haematology, urinalysis, vital signs, electrocardiogram, physical examination [ Time Frame: measured within 21 days of drug administration and up to 7 days following drug administration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of signed and dated, written informed consent prior to any study specific procedures
  • Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weight at least 50 kg and no more than 100 kg.

Exclusion Criteria:

  • Any clinically significant disease or disorder
  • Any clinically significant abnormalities at screening examination

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01161355

Layout table for location information
United Kingdom
Research Site
Ruddington, Nottingham, United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Study Director: Joanna Marks-Konczalik AstraZeneca
Principal Investigator: Sharan Sidhu, MB ChB, BAO, Quintiles, Inc.
Layout table for additonal information
Responsible Party: Medical Science Director, AstraZeneca Identifier: NCT01161355    
Other Study ID Numbers: D0520C00021
First Posted: July 13, 2010    Key Record Dates
Last Update Posted: February 9, 2011
Last Verified: February 2011
Keywords provided by AstraZeneca: